Dysplasia and carcinoma in situ of the urinary bladder

Antonio Lopez-Beltran, Rita C. Marques, Rodolfo Montironi, Carlos Reymundo, Jorge Fonseca, Liang Cheng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Urothelial dysplasia (low-grade intraurothelial neoplasia) is recognized as a premalignant urothelial lesion in the 2004 World Health Organization (WHO) classification system. Although clarification of the diagnostic criteria of urothelial dysplasia has improved in recent years, there is still a lack of interobserver reproducibility. Active clinical follow-up is mandatory in patients with a diagnosis of urothelial dysplasia since it constitutes a marker of urothelial instability, and disease progression, in up to 19% of cases. The differential diagnosis of urothelial dysplasia is with other flat urothelial lesions with atypia, including flat urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (highgrade intraurothelial neoplasia). In most cases, especially when small amounts of tissue are available, morphologic features alone may not be sufficient for diagnosis. Immunohistochemistry can be of help in selected cases, and a panel of cytokeratin 20, p53, and CD44 may help in the diagnosis. The use of HER2, p16, and Racemase remains as an option pending validation. Herein, we present the pathologic features and clinical significance of urothelial dysplasia and carcinoma in situ with emphasis on differential diagnosis from common flat lesions with atypia.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalAnalytical and Quantitative Cytology and Histology
Volume37
Issue number1
StatePublished - 2015

Fingerprint

Carcinoma in Situ
Urinary Bladder
Differential Diagnosis
Keratin-20
Racemases and Epimerases
Hyperplasia
Disease Progression
Neoplasms
Immunohistochemistry

Keywords

  • Bladder cancer
  • Carcinoma in situ
  • Diagnosis
  • Dysplasia
  • Intraurothelial neoplasia
  • Pathology
  • Reactive atypia
  • Urinary bladder
  • Urothelial dysplasia

ASJC Scopus subject areas

  • Anatomy
  • Histology
  • Medicine(all)

Cite this

Lopez-Beltran, A., Marques, R. C., Montironi, R., Reymundo, C., Fonseca, J., & Cheng, L. (2015). Dysplasia and carcinoma in situ of the urinary bladder. Analytical and Quantitative Cytology and Histology, 37(1), 29-38.

Dysplasia and carcinoma in situ of the urinary bladder. / Lopez-Beltran, Antonio; Marques, Rita C.; Montironi, Rodolfo; Reymundo, Carlos; Fonseca, Jorge; Cheng, Liang.

In: Analytical and Quantitative Cytology and Histology, Vol. 37, No. 1, 2015, p. 29-38.

Research output: Contribution to journalArticle

Lopez-Beltran, A, Marques, RC, Montironi, R, Reymundo, C, Fonseca, J & Cheng, L 2015, 'Dysplasia and carcinoma in situ of the urinary bladder', Analytical and Quantitative Cytology and Histology, vol. 37, no. 1, pp. 29-38.
Lopez-Beltran A, Marques RC, Montironi R, Reymundo C, Fonseca J, Cheng L. Dysplasia and carcinoma in situ of the urinary bladder. Analytical and Quantitative Cytology and Histology. 2015;37(1):29-38.
Lopez-Beltran, Antonio ; Marques, Rita C. ; Montironi, Rodolfo ; Reymundo, Carlos ; Fonseca, Jorge ; Cheng, Liang. / Dysplasia and carcinoma in situ of the urinary bladder. In: Analytical and Quantitative Cytology and Histology. 2015 ; Vol. 37, No. 1. pp. 29-38.
@article{dfd14b45d8cc4aca8c6a089a1aec7e95,
title = "Dysplasia and carcinoma in situ of the urinary bladder",
abstract = "Urothelial dysplasia (low-grade intraurothelial neoplasia) is recognized as a premalignant urothelial lesion in the 2004 World Health Organization (WHO) classification system. Although clarification of the diagnostic criteria of urothelial dysplasia has improved in recent years, there is still a lack of interobserver reproducibility. Active clinical follow-up is mandatory in patients with a diagnosis of urothelial dysplasia since it constitutes a marker of urothelial instability, and disease progression, in up to 19{\%} of cases. The differential diagnosis of urothelial dysplasia is with other flat urothelial lesions with atypia, including flat urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (highgrade intraurothelial neoplasia). In most cases, especially when small amounts of tissue are available, morphologic features alone may not be sufficient for diagnosis. Immunohistochemistry can be of help in selected cases, and a panel of cytokeratin 20, p53, and CD44 may help in the diagnosis. The use of HER2, p16, and Racemase remains as an option pending validation. Herein, we present the pathologic features and clinical significance of urothelial dysplasia and carcinoma in situ with emphasis on differential diagnosis from common flat lesions with atypia.",
keywords = "Bladder cancer, Carcinoma in situ, Diagnosis, Dysplasia, Intraurothelial neoplasia, Pathology, Reactive atypia, Urinary bladder, Urothelial dysplasia",
author = "Antonio Lopez-Beltran and Marques, {Rita C.} and Rodolfo Montironi and Carlos Reymundo and Jorge Fonseca and Liang Cheng",
year = "2015",
language = "English",
volume = "37",
pages = "29--38",
journal = "Analytical and Quantitative Cytopathology and Histopathology",
issn = "0301-102X",
publisher = "John Rylands University Library",
number = "1",

}

TY - JOUR

T1 - Dysplasia and carcinoma in situ of the urinary bladder

AU - Lopez-Beltran, Antonio

AU - Marques, Rita C.

AU - Montironi, Rodolfo

AU - Reymundo, Carlos

AU - Fonseca, Jorge

AU - Cheng, Liang

PY - 2015

Y1 - 2015

N2 - Urothelial dysplasia (low-grade intraurothelial neoplasia) is recognized as a premalignant urothelial lesion in the 2004 World Health Organization (WHO) classification system. Although clarification of the diagnostic criteria of urothelial dysplasia has improved in recent years, there is still a lack of interobserver reproducibility. Active clinical follow-up is mandatory in patients with a diagnosis of urothelial dysplasia since it constitutes a marker of urothelial instability, and disease progression, in up to 19% of cases. The differential diagnosis of urothelial dysplasia is with other flat urothelial lesions with atypia, including flat urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (highgrade intraurothelial neoplasia). In most cases, especially when small amounts of tissue are available, morphologic features alone may not be sufficient for diagnosis. Immunohistochemistry can be of help in selected cases, and a panel of cytokeratin 20, p53, and CD44 may help in the diagnosis. The use of HER2, p16, and Racemase remains as an option pending validation. Herein, we present the pathologic features and clinical significance of urothelial dysplasia and carcinoma in situ with emphasis on differential diagnosis from common flat lesions with atypia.

AB - Urothelial dysplasia (low-grade intraurothelial neoplasia) is recognized as a premalignant urothelial lesion in the 2004 World Health Organization (WHO) classification system. Although clarification of the diagnostic criteria of urothelial dysplasia has improved in recent years, there is still a lack of interobserver reproducibility. Active clinical follow-up is mandatory in patients with a diagnosis of urothelial dysplasia since it constitutes a marker of urothelial instability, and disease progression, in up to 19% of cases. The differential diagnosis of urothelial dysplasia is with other flat urothelial lesions with atypia, including flat urothelial hyperplasia, reactive urothelial atypia, urothelial atypia of unknown significance, and urothelial carcinoma in situ (highgrade intraurothelial neoplasia). In most cases, especially when small amounts of tissue are available, morphologic features alone may not be sufficient for diagnosis. Immunohistochemistry can be of help in selected cases, and a panel of cytokeratin 20, p53, and CD44 may help in the diagnosis. The use of HER2, p16, and Racemase remains as an option pending validation. Herein, we present the pathologic features and clinical significance of urothelial dysplasia and carcinoma in situ with emphasis on differential diagnosis from common flat lesions with atypia.

KW - Bladder cancer

KW - Carcinoma in situ

KW - Diagnosis

KW - Dysplasia

KW - Intraurothelial neoplasia

KW - Pathology

KW - Reactive atypia

KW - Urinary bladder

KW - Urothelial dysplasia

UR - http://www.scopus.com/inward/record.url?scp=84925362078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925362078&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 29

EP - 38

JO - Analytical and Quantitative Cytopathology and Histopathology

JF - Analytical and Quantitative Cytopathology and Histopathology

SN - 0301-102X

IS - 1

ER -